Welcome to Cancer Immunotherapy: A Long-Awaited Reality Conference

William Blair and MaidStone Life Sciences have organized a unique, single-day conference that unites founding visionary researchers, clinicians, biotech/pharma executives, key investors, equity research analysts, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy. The day will consist of a series of talks and panels from leading experts from across the immuno-oncology spectrum.

Driven by innovative research and development, collaborations of academia and industry, the formation of new companies, product approvals, and advances in cancer treatments and diagnostics, the immuno-oncology field is evolving rapidly, which should create numerous opportunities in the biotech/pharma space. This conference should help the participants explore and begin to define the dynamics and key issues that will drive the sector over the next 12 to 24 months.

We hope that the presentations and our perspectives will make for a productive and enjoyable conference. Thank you for joining us, and we look forward to visiting with you.

John Sonnier  
William Blair  
+1 312 364 8224  
jsonnier@williamblair.com

Y. Katherine Xu, Ph.D.  
William Blair  
+1 212 237 2758  
kxu@williamblair.com

Janet L. Dally  
MaidStone Life Sciences  
+1 609 466 0466  
JanetDally@MaidStoneLifeSci.com

The day's event is divided into five main sections:

- Keynote Speech
- Checkpoint/Immunomodulators
- Therapeutic Vaccines: Stimulating the Immune System
- Adoptive Cell Therapies
- Combination Immuno-oncology Themes

This book contains the following information:

- Agenda
- Organizer bios
- Speaker bios (in order of appearance)
In Memoriam: Holbrook Kohrt, M.D., Ph.D.
1977–2016

Holbrook Kohrt, M.D., Ph.D., was an esteemed member of the immuno-oncology field and a major contributor to this conference.

His dedication and strategic clinical and scientific insights were instrumental in making this cancer immunotherapy conference a success. It was a true privilege to collaborate with one of the most inspirational, creative, passionate, and brilliant scientists in this field, and we are deeply saddened that he is no longer with us. Dr. Kohrt leaves an incredible legacy as an innovator in the field of immuno-oncology as a clinician, scientist, and advisor to a number of biotech and pharma companies.

An assistant professor of medicine (oncology) at the Stanford Cancer Institute investigating novel therapeutic strategies to enhance anti-tumor immunity, Dr. Kohrt struggled all his life with hemophilia.

He attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar, and American Society of Hematology Research Fellow. He trained in internal medicine at Stanford through the Clinical Investigator Pathway and completed his fellowship in hematology and oncology at Stanford, with a research focus on preclinical models of novel immunomodulatory antibodies. Dr. Kohrt received his Ph.D. in clinical trial design and tumor immunology from Stanford with a thesis that included the first report of an agonistic monoclonal antibody capable of enhancing the efficacy of tumor-targeting therapeutics.

As faculty at Stanford, Dr. Kohrt developed novel vaccine strategies that induce tumor antigen-specific immunity prior to infusing the donor inoculum and improve graft-versus-tumor reactions without exacerbation of graft-versus-host disease. His research included efforts to identify and develop immunomodulatory antibodies targeting immune effector cells subsets, such as natural killer cells, which enhance the anti-tumor activity of tumor-targeting antibodies. He was a leader in the clinical development of agents including IL-15, IL-7, anti-CTLA-4, anti-CD137, anti-PD-1, anti-PD-L1, BTK inhibitors, and HPV-targeted and WT1-targeted vaccines.

Our heartfelt condolences go to his family, friends, colleagues, and patients.
Cancer Immunotherapy: A Long-Awaited Reality Conference

March 31, 2016

7:30–8:00 a.m.  *Registration*

8:00–8:05  Opening Remarks

8:05–8:45  **Keynote Speech: Immuno-oncology: Past, Present, and Future**
Carl P. Decicco, Ph.D., Senior Vice President and Head–Discovery, Bristol-Myers Squibb

8:45–9:00  Discovering and Developing Immunomodulating Therapies to Treat Cancer
Robert Sikorski, M.D., Ph.D., Senior Vice President–Global Clinical Development, Five Prime Therapeutics

9:00–9:10  **Toll-Like Receptor Agonists in Cancer Immunotherapy**
Robert L. Coffman, Ph.D., Senior Vice President and CSO, Dynavax

9:10–9:20  Direct Activation of STING to Induce a Systemic T-Cell Response Specific for an Individual’s Unique Tumor Antigen Repertoire
Thomas W. Dubensky, Jr., Ph.D., CSO, Aduro Biotech

9:20–9:30  **NKTR-214, a T-Cell Growth Engine for Immuno-oncology**
Deborah Charych, Ph.D., Executive Director–Research Biology, Nektar Therapeutics

9:30–9:45  **Spatial Mapping to Define the Immune Landscape in Cancer**
Paul Tumeh, M.D., Assistant Professor in Residence, Division of Dermatology, UCLA

9:45–10:15  **Panel Discussion**
*Moderator:* Robert Stein, M.D., Ph.D., President–Research and Development and CSO, Agenus

10:15–10:30  **Coffee Break**

10:30–10:45  **Next-Generation Cancer Vaccines**
Col. (ret.) George E. Peoples, M.D., FACS, MC, USA, Founder and CEO, Cancer Insight, LLC; Director–Cancer Vaccine Development Program; Professor, Surgery, Uniformed Services University; Professor (adj.), Surgical Oncology, MD Anderson Cancer Center

10:45–11:00  Understanding and Optimizing In Situ Vaccination
Joshua Brody, M.D., Director–Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine

11:00–12:00 p.m.  **Panel Discussion**
*Moderator:* James Gulley, M.D., Ph.D., Chief–Genitourinary Malignancies Branch; Head–Immunotherapy Section; Director–Medical Oncology Service, Center for Cancer Research, NIH

11:00–12:00 p.m.  **Panel Discussion**
*Moderator:* James Gulley, M.D., Ph.D., Chief–Genitourinary Malignancies Branch; Head–Immunotherapy Section; Director–Medical Oncology Service, Center for Cancer Research, NIH

Col. (ret.) George E. Peoples, FACS, MC, USA, Founder and CEO, Cancer Insight, LLC; Director, Cancer Vaccine Development Program; Professor, Surgery, Uniformed Services University; Professor (adj.), Surgical Oncology, MD Anderson Cancer Center

Robert Stein, M.D., Ph.D., President–Research and Development and CSO, Agenus

Robert Sikorski, M.D., Ph.D., Senior Vice President–Global Clinical Development, Five Prime Therapeutics

Deborah Charych, Ph.D., Executive Director–Research Biology, Nektar Therapeutics

Reiner Laus, M.D., President and CEO, Annias Immunotherapeutics
Joshua Brody, M.D., Director–Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine
Taylor Schreiber, M.D., Ph.D., CSO, Heat Biologics
Thomas W. Dubensky, Jr, Ph.D., CSO, Aduro Biotech
Niranjan Sardesai, Ph.D., COO, Inovio
Charles A. Nicolette, Ph.D., Vice President–Research and Development and CSO, Argos Therapeutics, Inc.

2:45–3:00

Coffee Break

Combination Immuno-oncology Themes

3:00–3:15

Immunosequencing in Immuno-oncology/Tumor Micro-Environment
Ilan "Lanny" Kirsch, M.D., Senior Vice President–Translational Medicine, Adaptive Biotechnologies

Targeting the Immunosuppressive Microenvironment
Julian Adams, Ph.D., President–Research and Development, Infinity Pharmaceuticals

Emerging Biomarkers in Immuno-oncology
Michael Kalos, Ph.D., CSO–Cancer Immunobiology, Lilly Research Laboratories, Eli Lilly and Company

Integrated Approach to Optimizing Cancer Immunotherapy
Robert Stein, M.D., Ph.D., President–Research and Development and CSO, Agenus

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells
John Lin, M.D., Ph.D., Senior Vice President and CSO, Rinat (Pfizer)

The Increasing Relevance of Vaccines in the Era of Checkpoints
James Gulley, M.D., Ph.D., Chief–Genitourinary Malignancies Branch; Head–Immunotherapy Section; Director–Medical Oncology Service, Center for Cancer Research, NIH

4:30–5:15

Panel Discussion

Moderator: James Gulley, M.D., Ph.D., Chief–Genitourinary Malignancies Branch; Head–Immunotherapy Section; Director–Medical Oncology Service, Center for Cancer Research, NIH
Robert Stein, M.D., Ph.D., President–Research and Development and CSO, Agenus
Robert Sikorski, M.D., Ph.D., Senior Vice President–Global Clinical Development, Five Prime Therapeutics
Paul Tumeh, M.D., Assistant Professor in Residence, Division of Dermatology, UCLA
Taylor Schreiber, M.D., Ph.D., CSO, Heat Biologics
Michael Kalos, Ph.D., CSO–Cancer Immunobiology, Lilly Research Laboratories, Eli Lilly and Company
John Lin, M.D., Ph.D., Senior Vice President and CSO, Rinat (Pfizer)

5:15–5:20  Closing Remarks
5:20 p.m.  Wine and Cheese Networking Reception

Apella, Event Space at Alexandria Center
450 East 29th Street
New York, New York

Please contact us at +1 800 621 0687 or consult williamblair.com/Research-and-Insights/Equity-Research/Coverage.aspx for all disclosures.
John Sonnier
Biotechnology Analyst
William Blair & Company, L.L.C.

Y. Katherine Xu, Ph.D.
Biotechnology Analyst
William Blair & Company, L.L.C.

John Sonnier, partner, joined William Blair in September 2005 to build the firm’s biotechnology equity research practice. Before joining William Blair, Mr. Sonnier was a biotechnology equity research analyst for seven years with the Prudential Equity Group. He began his career on Wall Street at Vector Securities International, where he served in roles of increasing responsibility in equity research, lastly as partner. Mr. Sonnier brings a wealth of biopharmaceutical industry experience to William Blair, having spent eight years in various commercial and strategic roles at Johnson & Johnson and Baxter International. He holds a Master of Public Health degree from Johns Hopkins University.

Y. Katherine Xu, Ph.D., partner, joined William Blair in March 2011 as a biotechnology analyst. Ms. Xu previously was senior vice president and senior biotechnology analyst at Wedbush Securities, vice president and senior biotechnology analyst at Credit Suisse, and a senior biotechnology analyst at Pacific Growth Equities. Ms. Xu was recognized by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock-picking in the United States in 2010, and No. 2 for stock-picking in biotechnology in 2011; she received the No. 2 ranking in The Wall Street Journal’s “Best on the Street” listing in 2011 as well. Before her move to equity research, Ms. Xu worked in investment banking for two years. Ms. Xu holds a Ph.D. in developmental biology and a Ph.D. minor in engineering-economic systems and operations research from Stanford University Schools of Medicine and Engineering, respectively, and worked on a postdoctoral project in bioinformatics at the Department of Mathematics, Stanford University. She attended Peking University in Beijing and Kalamazoo College in Michigan, where she gained her B.A. with honors.
Janet L. Dally has more than 20 years of experience in the biotechnology, pharmaceutical, and medical technology industries as an investor relations advisor, healthcare fund analyst, business development and medical device marketing manager, and microbiologist. She is an active advocate for the biotechnology industry.

Before establishing MaidStone Life Sciences, Ms. Dally was senior partner at MD Becker Partners. Prior to this, she was president of MontRidge, LLC, a boutique investor relations and strategic consulting firm specializing in the life science industry. During her tenure at these firms, Ms. Dally built meaningful relationships with the executive management of life science clients and the U.S. and European investment communities, resulting in increased institutional ownership, diversified shareholder base, sell-side analyst coverage, enhanced valuation, and successful financing.

Prior to MontRidge, Ms. Dally was vice president of investor relations at Burns McClellan, a life sciences communication firm. She was also a buy-side analyst for six years for the Merrill Lynch Healthcare Fund, evaluating and recommending biotechnology, pharmaceutical, medical device, and healthcare services firms. She previously held executive positions in strategic planning, business development, licensing, and M&A at Sterling Drug and Forest Laboratories.

Ms. Dally has an M.B.A. from the Tepper School of Business, Carnegie Mellon University; an M.S. in microbiology from Wagner College; and a B.S. in medical technology from Rutgers University.
Keynote Speech: Immuno-oncology: Past, Present, and Future

Carl P. Decicco, Ph.D.
Senior Vice President and Head–Discovery
Bristol-Myers Squibb Company

Dr. Carl Decicco leads the discovery organization at Bristol-Myers Squibb and is a member of the BMS R&D Senior Leadership Team reporting to the chief scientific officer.

Dr. Decicco began his career in the pharmaceutical industry in 1991 at DuPont Merck and then DuPont Pharmaceuticals where he made significant contributions in virology, inflammatory diseases, neuroscience, and cardiovascular research. In 2001 he joined Bristol-Myers Squibb as the head of discovery chemistry and most recently was appointed head of discovery in 2013. With his teams, he has progressed more than 140 new chemical entities into development, several of which have advanced into late-stage clinical testing. He has been a part of the BMS leadership team that has achieved 14 NDAs over the last 10 years, including Onglyza and Forxiga for diabetes, Daklinza and Sunvepra for hepatitis C, and two immunotherapeutics for cancer, Yervoy and Opdivo.

Dr. Decicco completed postdoctoral studies with Professor E. J. Corey (Nobel laureate 1990) at Harvard University, was a teaching fellow at the University of British Columbia, and obtained his Ph.D. with Professor Gordon Lange in organic chemistry from the Guelph-Waterloo Center in Ontario, Canada.

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global bio-pharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. The company’s medicines are helping patients in their fight against cancer, cardiovascular disease, hepatitis C, HIV, and rheumatoid arthritis. Bristol-Myers Squibb has a vision for the future of cancer care that is focused on immuno-oncology, now considered a major treatment choice alongside surgery, radiation, chemotherapy, and targeted therapies for certain types of cancer. In addition to immuno-oncology, other emerging platforms of interest include cardiovascular diseases, fibrotic diseases, genetically defined disease, and immunoscience.
Checkpoint/Immunomodulators
Discovering and Developing Immunomodulating Therapies to Treat Cancer

Robert Sikorski, M.D., Ph.D.
Senior Vice President–Global Clinical Development
Five Prime Therapeutics, Inc.

Dr. Sikorski has served as Five Prime’s senior vice president of global clinical development since January 2016. He previously served as vice president of global clinical development from September 2014 to January 2016. From December 2010 to September 2014 he was senior director of global oncology research and development at MedImmune, leading the development of a portfolio of oncology therapeutics with a focus on immune-mediated therapies. Prior to joining MedImmune, he was director of global oncology research and development at Amgen, where he led the development of several oncology drug candidates. Here, Dr. Sikorsky played a key role in achieving marketing approval for Vectibix based on a first-in-class biomarker. In earlier positions, he served as a medical affairs consultant to Genzyme and as chief technology officer at the biomedical data acquisition and analytics firm, Mednav. Dr. Sikorski received his M.D. and Ph.D. from The Johns Hopkins University School of Medicine through a Medical Scientist Training Program scholarship. He completed his residency at Massachusetts General Hospital and an oncology fellowship at The Johns Hopkins Oncology Center; he is board certified in both oncology and internal medicine. Dr. Sikorski began his career as a Howard Hughes Research Fellow and visiting scientist at the National Cancer Institute and the National Human Genome Research Institute in the laboratory of Nobel Laureate Harold Varmus.

Five Prime Therapeutics, Inc.
Five Prime Therapeutics discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime’s comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation, and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company’s R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, visit www.fiveprime.com.

Toll-Like Receptor Agonists in Cancer Immunotherapy

Robert L. Coffman, Ph.D.
Senior Vice President and Chief Scientific Officer
Dynavax Technologies Corporation

Robert Coffman, Ph.D., is senior vice president and chief scientific officer of Dynavax Technologies Corporation in Berkeley, California. Prior to joining Dynavax in 2000, he was a founding member of the DNAX Research Institute in Palo Alto, California. Dr. Coffman has authored more than 200 scientific publications, is a member of the National Academy of Sciences and the American Academy of Microbiology, and has received a number of prestigious awards for his work.

With colleague Dr. Tim Mosmann, he defined the two principal subtypes of helper T cells, termed Th1 and Th2 cells, and demonstrated the central relationship between their differences in cytokine expression and function. Dr. Coffman defined basic mechanisms of T-cell regulation in asthma and infectious and parasitic diseases, and demonstrated the central role of regulatory CD4+ T cells in preventing inflammatory bowel disease. At Dynavax, Dr. Coffman has pioneered the development of agonists and antagonists for Toll-like receptors, key recognition receptors in innate immunity.

Dynavax Technologies Corporation
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax’s lead product candidates are HEPLISAV-B™, a Phase III investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase I/II studies. For more information, visit www.dynavax.com.
Direct Activation of STING to Induce a Systemic T-Cell Response Specific for an Individual’s Unique Tumor Antigen Repertoire

Thomas W. Dubensky, Jr., Ph.D.
Chief Scientific Officer, Aduro Biotech, Inc.

Dr. Thomas Dubensky has served as chief scientific officer of Aduro Biotech since September 2011. From 2009 to 2011, he served as chief scientific officer of Immune Design Corp., a biotechnology company, where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms. He was a co-founder and CSO of Anza Therapeutics, Inc., a biotechnology company that was spun out from Cerus Corporation in 2007, where he served as the vice president of research beginning in 2002. At Cerus and at Anza, he helped develop vaccine platforms based on attenuated strains of Listeria monocytogenes, which serves as the technology basis for Aduro. Previously, Dr. Dubensky developed vaccine platforms based on alphaviruses, adenoviruses, retroviruses/lentiviruses, and plasmid DNA in positions of increasing responsibility at Viagene Biotech, Inc., Chiron Corporation, and Onyx Pharmaceuticals, Inc., all biotechnology companies. He has co-authored more than 70 scientific papers and is an inventor on 34 issued U.S. patents and multiple pending applications. Dr. Dubensky received his B.A. in bacteriology and immunology from the University of California, Berkeley; he earned his Ph.D. at the University of Colorado Health Sciences Center; and he was a post-doctoral fellow at Harvard Medical School in the Department of Pathology.

Aduro Biotech, Inc.
Aduro is an immunotherapy company focused on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. Aduro’s technology platforms, which are designed to harness the body’s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, visit www.aduro.com.

NKTR-214, a T-Cell Growth Engine for Immun oncology

Deborah Charych, Ph.D.
Executive Director–Research Biology, Nektar Therapeutics

Dr. Deborah Charych has held senior scientific leadership positions in both academia and biotechnology. At Nektar Therapeutics, she heads the immunotherapy pipeline and identified a novel approach to modulate tumor immunology using polymer conjugation technology. This work led to the development of NKTR-214, a biased agonist of the IL-2 pathway, in Phase I clinical development. The pipeline also consists of other immune modulating cytokine and small molecule conjugates. At Five Prime Therapeutics, Deborah led a team focused on matching orphan receptor-ligand pairs to identify new biological pathways and targets. Dr. Charych was also a key contributor to the clinical development of FP-1039, a pan-FGF inhibitor for oncology now in Phase II clinical trials. As director of Five Prime’s process development group, she led the downstream process development and manufacturing of several complex biologics for oncology and inflammation scaling from research to GMP manufacturing. While at Chiron Corporation, she initiated and led a large scale proteomics effort to guide oncology target discovery. At Lawrence Berkeley National Laboratory, she quickly assumed an academic leadership role as principal investigator, focusing on new polymeric materials for biosensor applications. Dr. Charych’s formal education is in chemistry. She earned a Ph.D. from University of California at Berkeley and a B.S. in chemistry from Carnegie-Mellon University, Pittsburgh.

Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that use its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. Nektar’s research and development activities involve small molecule drugs, peptides, and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism, or distribution of drugs and improve the overall benefits and use of a drug for the patient.
Spatial Mapping to Define the Immune Landscape in Cancer

Paul Tumeh, M.D.
Assistant Professor in Residence, Division of Dermatology, UCLA

Dr. Paul C. Tumeh is currently an assistant professor in residence in the Division of Dermatology at UCLA. He has a melanoma specialty clinic and serves as a sub-investigator on all melanoma immunotherapy clinical trials at UCLA Medical Center. His translational immunology research program has two main objectives: 1) identify niches (i.e., discrete cellular microenvironments) within tumors that drive or inhibit response to therapies that block the PD1/PDL1 axis, and 2) isolate distinct cell-types (e.g., myeloid-derived cells) from their native microenvironment to investigate the molecular mechanisms underlying response and nonresponse to anti-PD-1 therapy. He is currently focused on understanding the phenotype and function of PD-L1+ myeloid-derived cells at the invasive tumor margin and how these cells may determine treatment outcome. His latest publications include articles in *Nature, New England Journal of Medicine*, and *Clinical Cancer Research*. 
Panel Discussion

Bios for the panelists who have presented or will present can be found in the indicated section of the book. Otherwise, they begin on the following page.

**Moderator: Robert Stein, M.D., Ph.D.,** President–Research and Development and CSO, Agenus (Combination Immuno-oncology Themes)

**Robert Sikorski, M.D., Ph.D.,** Senior Vice President–Global Clinical Development, Five Prime Therapeutics (Checkpoint/Imnomodulators)

**Deborah Charych, Ph.D.,** Executive Director–Research Biology, Nektar (Checkpoint/Imnomodulators)

**Thomas W. Dubensky, Jr., Ph.D.,** CSO, Aduro Biotech (Checkpoint/Imnomodulators)

**Robert L. Coffman, Ph.D.,** Senior Vice President and CSO, Dynavax (Checkpoint/Imnomodulators)

**Paul Tumeh, M.D.,** Assistant Professor in Residence, Division of Dermatology, UCLA (Checkpoint/Imnomodulators)
Notes
Therapeutic Vaccines: Stimulating the Immune System
Next-Generation Cancer Vaccines

Colonel (Retired) George E. Peoples, M.D., FACS
Founder and CEO, Cancer Insight, LLC
Director–Cancer Vaccine Development Program
Professor of Surgery, Uniformed Services University
Professor (adjunct) of Surgical Oncology, MD Anderson Cancer Center

Dr. George E. Peoples recently retired from 30 years of active duty as a surgeon and research scientist in the military. He is the founder and director of the Cancer Vaccine Development Program (CVDP), which is associated with the Uniformed Services University of the Health Sciences (USUHS), Bethesda, Maryland. The CVDP has 15 years of experience in discovering, developing, and clinical testing of cancer vaccines—four of which have been licensed for commercial development. With his retirement, the CVDP now has a commercial counterpart, Cancer Insight, LLC, which is a boutique cancer immunotherapy CRO currently conducting multiple Phase I and II trials. Dr. Peoples serves as the CEO of Cancer Insight.

In addition, Dr. Peoples is a professor of surgery at USUHS, and professor (adjunct) of surgical oncology at MD Anderson Cancer Center. He is the past chair of the Cancer Program, San Antonio Military Medical Center and the past deputy director of the United States Military Cancer Institute. He is a graduate of the United States Military Academy, West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard’s Brigham and Women’s Hospital and a surgical oncology fellowship at MD Anderson Cancer Center. He has written extensively on the immune response to cancer with more than 300 peer-reviewed manuscripts, abstracts, and book chapters.

Understanding and Optimizing In Situ Vaccination

Joshua Brody, M.D.
Director–Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine

Joshua Brody, M.D., is an assistant professor in hematology and medical oncology and the director of the Lymphoma Immunotherapy Program at the Mount Sinai School of Medicine in New York City. He is also a Damon Runyon Cancer Research Foundation clinical investigator, a member of the Lymphoma Research Foundation’s (LRF’s) Mantle Cell Lymphoma Consortium, and an LRF Career Development Award grant recipient.

Dr. Brody received his M.D. from State University of New York, Stony Brook School of Medicine and his B.A. in molecular and cellular biology from Harvard University. He completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in medical oncology at Stanford University School of Medicine. With clinical focus in chronic lymphoid leukemia, cutaneous lymphomas, follicular lymphoma, mantle cell lymphoma, and post-transplant lymphoproliferative disorders, his lab at Mount Sinai centers on basic and applied tumor immunology.

Dr. Brody’s current research focuses on two areas: lymphoma immunotherapy and a class of targeted therapies called B-cell receptor signaling inhibitors. His group developed an approach called in situ vaccination in which an immune stimulant is injected directly into one lymphoma tumor, but can then induce an anti-tumor immune response that travels throughout the body to eliminate tumors systemically. Preclinical models and early phase clinical trials have demonstrated durable regressions of even bulky and advanced stage tumors and show promise as a novel modality toward a cure for these difficult diseases.
Panel Discussion

Bios for the panelists who have presented or will present can be found in the indicated section of the book. Otherwise, they begin on the following page.

Moderator: James Gulley, M.D., Ph.D., Chief-Genitourinary Malignancies Branch; Head-Immunotherapy Section; Director-Medical Oncology Service, Center for Cancer Research, NIH (Combination Immunoncology Themes)

Col. (ret.) George E. Peoples, M.D., FACS, Founder and CEO, Cancer Insight, LLC; Director, Cancer Vaccine Development Program; Professor, Surgery, Uniformed Services University; Professor (adj.), Surgical Oncology, MD Anderson Cancer Center (Therapeutic Vaccines: Stimulating the Immune System)

Robert Stein, M.D., Ph.D., President-Research and Development and CSO, Agenus (Combination Immunoncology Themes)

Reiner Laus, M.D., President and CEO, Annias Immunotherapeutics

Joshua Brody, M.D., Director-Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine (Therapeutic Vaccines: Stimulating the Immune System)

Taylor Schreiber, M.D., Ph.D., CSO, Heat Biologics

Thomas W. Dubensky, Jr., Ph.D., CSO, Aduro Biotech (Checkpoint/Immunomodulators)

Niranjan Sardesai, Ph.D., COO, Inovio

Charles A. Nicolette, Ph.D., Vice President-Research and Development and CSO, Argos Therapeutics, Inc.
Reiner Laus, M.D.
President and Chief Executive Officer, Annias Immunotherapeutics, Inc.

Reiner Laus, M.D., has worked on developing cancer immunotherapeutics for more than 20 years. At BN ImmuNoTherapeutics, he focused on the development of recombinant poxviral vaccines, including PROSTVAC and CV301 for the immunotherapy of cancer. Prior to this, Dr. Laus held the position of vice president of research and development at Dendreon Corporation, where he worked for 11 years since the company’s inception in 1993. During his tenure at Dendreon, Dr. Laus invented PROVENGE, the first cancer vaccine to get approved by the FDA, and he was instrumental in its development. He is also author of key patents relating to this product. Previously, Dr. Laus held academic appointments at the University of Kiel, Germany and at Stanford University, California.

Annias Immunotherapeutics, Inc.
Annias is a clinical stage immuno-oncology company focused on the development of novel immunotherapeutic approaches to the treatment of cancers that contain Cytomegalovirus (CMV). The company’s approach is based on a patented and proprietary immunotherapeutic platform discovered at Duke University, which harnesses the body’s immune system to recognize, attack, and destroy tumor cells containing CMV. CMV is overexpressed in a variety of human cancers, including significant and homogeneous expression in almost all glioblastoma, but not in normal brain tissue. Annias Immunotherapeutics focuses on this opportunity to use CMV proteins as tumor-specific targets.

Taylor Schreiber, M.D., Ph.D.
Chief Scientific Officer, Heat Biologics, Inc.

Dr. Schreiber leads Heat Biologics’ preclinical drug development and scientific operations. As a cancer biologist and drug development scientist, Dr. Schreiber possesses more than 15 years of laboratory experience in the discovery of novel therapeutic immuno-oncology compounds. He is the co-inventor of significant elements of Heat’s ImPACT and ComPACT immunotherapy platforms as well as a co-inventor of TNFRSF25 agonist technologies. Dr. Schreiber received his Ph.D. from the Sheila and David Fuente Program in cancer biology and his M.D. at the University of Miami Miller School of Medicine. He completed his post-doctoral fellowship with the original inventor of Heat’s ImPACT technology platform, Eckhard R. Podack, M.D., Ph.D., studying the immunobiology of TNFRSF25. Dr. Schreiber has authored more than 25 peer-reviewed tumor immunology and heat shock protein-based cancer immunotherapy publications. In 2011, he was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research.

Heat Biologics, Inc.
Heat Biologics is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T-cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ killer T cells (one of the human immune system’s most potent weapons against cancer); T-cell co-stimulation to further enhance patients’ immune response; and reversal of tumor-induced immune suppression. Currently, Heat is conducting a Phase II trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase Ib trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small-cell lung cancer (NSCLC). For more information, visit www.heatbio.com.
Niranjan Sardesai, Ph.D.
Chief Operating Officer, Inovio Pharmaceuticals, Inc.

Niranjan Y. Sardesai, Ph.D., is Inovio’s chief operating officer, responsible for research and development, engineering, manufacturing, and business development. He previously founded and was president of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as director of research and development at Fujirebio Diagnostics, Inc., where he oversaw the expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma (MESOMARK™), bladder cancer, and a multi-marker test for ovarian cancer.

Dr. Sardesai received a Ph.D. in chemistry from the California Institute of Technology and an M.B.A. (entrepreneurship and finance) from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his bachelor’s and master’s of science degrees in chemistry from the Indian Institute of Technology, Bombay. He has authored more than 100 peer-reviewed manuscripts and book chapters, with particular contributions in vaccines and immunotherapies, oncology, and medical devices; presented at over 120 invited lectures and presentations; and filed several patents.

Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and infectious diseases. The company’s immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

Charles A. Nicolette, Ph.D.
Vice President–Research and Development and Chief Scientific Officer, Argos Therapeutics, Inc.

Charles A. Nicolette, Ph.D., has served as chief scientific officer for Argos Therapeutics since December 2007 and as vice president of research and development since December 2004. He served as vice president of research from July 2003 to December 2004. From 1997 to 2003, Dr. Nicolette served in various positions at Genzyme Molecular Oncology, Inc., a biotechnology company, most recently as director of Antigen Discovery. Dr. Nicolette received a B.S. from the State University of New York at Stony Brook and a Ph.D. in biochemistry and cellular and developmental biology from the State University of New York at Stony Brook, completing his doctoral dissertation and post-doctoral fellowship at Cold Spring Harbor Laboratory.

Argos Therapeutics, Inc.
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform. Argos’s most-advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase III clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of HIV, which is currently being evaluated in a Phase II clinical trial aimed at HIV eradication in adult patients.
Adoptive Cell Therapies
CARS and Armored CARS

Renier Brentjens, M.D., Ph.D.
Director–Cellular Therapeutics, Memorial Sloan Kettering Cancer Center

Dr. Renier Brentjens earned his M.D. and Ph.D. in microbiology from The State University of New York at Buffalo, School of Medicine and Biomedical Sciences, completed his residency at Yale-New Haven Hospital, and was granted a medical oncology fellowship from Memorial Sloan Kettering Cancer Center (MSKCC).

Currently, Dr. Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service. As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated preclinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T-cell receptors, termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr. Brentjens became the principle investigator of his own laboratory. In this role, he successfully translated the latter studies to the clinical setting treating patients with relapsed CD19+ tumors, including chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia. Ongoing preclinical research in the laboratory is focused on the further development of CAR-modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second-generation CAR-modified T-cell clinical trials.

In his lab, Dr. Brentjens has expanded this CAR technology to target additional tumor antigens expressed on other tumors including targeting the MUC-16 antigen expressed on ovarian carcinomas and the more ubiquitous WT-1 tumor associated antigen. These latter projects are similarly in the process of translation to the clinical setting.

CAR T Cells at the Crossroads: Where Do We Go From Here?

Marcela Maus, M.D., Ph.D.
Director–Cellular Immunotherapy, Massachusetts General Hospital

Dr. Marcela Maus has extensive experience in gene and cell therapies, in particular the biology of T-cell activation and clinical translation of adoptive immunotherapy, including regulatory and clinical expertise with gene-modified T cells. She has 15-plus years of basic laboratory research experience and is board-certified in internal medicine, medical oncology, and hematology, with particular clinical training in melanoma, myeloma, and bone marrow transplant. Dr. Maus has unique expertise in bringing novel cell and gene therapies from the laboratory to the clinic, including the local and federal regulatory processes mandated for clinical translational medicine. Leading multidisciplinary teams of scientists and clinicians, she has successfully opened trials of genetically modified T cells in multiple myeloma, leukemia, mesothelioma, pancreatic, and ovarian cancers, and glioblastoma multiforme. In her new position at the Massachusetts General Hospital Cancer Center, Dr. Maus runs a laboratory that continues to focus on optimal T-cell engineering for use as adoptive immunotherapy. She directs the Cellular Immunotherapy Program at MGH, which includes a Phase I immuno-oncology clinical unit. In this role, Dr. Maus oversees the clinical and translational research portfolio in T-cell therapies at MGH.

Dr. Maus received her M.D. in internal medicine and her Ph.D. in cell and molecular biology from the University of Pennsylvania School of Medicine.
Harnessing Tumour Antigen Recognition by TCRs: Today and Beyond

Helen Tayton-Martin, Ph.D.
Chief Operating Officer, Adaptimmune

Dr. Helen Tayton-Martin co-founded Adaptimmune and has served as the chief operating officer since July 2008. She is responsible for strategic research-and-development planning, specifically focused on business development and commercial activities, including the company’s strategic partnership with GlaxoSmithKline.

Dr. Tayton-Martin has 23 years of experience working within the pharma, biotech, and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence, and business development. Prior to Adaptimmune, she was at Avidex Limited (subsequently Medigene) where she was responsible for commercial development of the soluble TCR programme in cancer and HIV therapy from 2005 to 2008. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K., and an M.B.A. from London Business School.

Adaptimmune Therapeutics plc

Adaptimmune is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery—the T cell—to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity-enhanced T-cell therapy targeting the NY-ESO cancer antigen.

Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, the company has a number of proprietary programs. It has identified more than 30 intracellular target peptides preferentially expressed in cancer cells and is progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K., and Philadelphia, Pennsylvania.

The Power of Allogeneic T-Cell Banks Targeting Multiple Viral and Cancer Antigens

Christopher Haqq, M.D., Ph.D.
Chief Medical Officer, Atara Biotherapeutics

Dr. Christopher Haqq joined Atara Biotherapeutics as chief medical officer in September 2012. He brings 20 years of clinical, academic, and drug development experience from biopharma companies large and small. He was recently vice president of clinical research and development at Cougar Biotechnology and Johnson & Johnson’s Janssen, where he was the lead clinician for a pivotal prostate cancer study leading to market approval for Zytiga® (abiraterone acetate). Previously at Amgen, he led early-development studies of the anti-insulin-like growth factor type 1 receptor AMG 479 (ganitumab) antibody. He has served as medical monitor for more than 10 clinical trials and has contributed to drug development programs for a wide range of molecules. Dr. Haqq has worked closely with the European Medicines Agency, the U.S. FDA, and other global regulatory agencies, filing IND applications, new drug applications, special protocol assessments, and their international equivalents. Earlier in his career, he practiced as a medical oncologist and led a translational science laboratory as an assistant adjunct professor in the Division of Hematology/Oncology at the University of California, San Francisco. In his post-graduate training, also at UCSF, he served as an intern and resident in internal medicine, fellow in medical oncology, and fellow in molecular medicine. Dr. Haqq completed his M.D. and Ph.D. at Harvard Medical School and his B.S. at Stanford University. He is board certified in medical oncology and internal medicine. He is an inventor of three patents and an author of nearly 50 medical publications.

Atara Biotherapeutics

Atara Bio is a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Its programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL, and WT1-CTL, and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434, which target members of the TGF-beta family of proteins and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
Targeting Cancer Cells Inside and Out: TCRs and CARs

Margo Roberts, Ph.D.
Chief Scientific Officer, Kite Pharma

Dr. Roberts has more than two decades of biomedical research, drug discovery, and development experience. From 1999 to 2013, Dr. Roberts held an associate professor position at the University of Virginia where she pursued interdisciplinary research in the area of immunity and inflammation. From 1990 to 1998, she served as principal scientist and director of immune and cell therapy at Cell Genesys, Inc. There, she led the development of chimeric antigen receptor (CAR) technology, encompassing CAR design and function in T cells and stem cells, along with related methodologies for T-cell engineering. She oversaw the application of CAR technology to HIV disease and, under her leadership, the CD4z CAR T-cell research program culminated in the first CAR T-cell clinical trial initiated in 1994. Dr. Roberts is the inventor on the first set of CAR patents, including second-generation CAR constructs that incorporate the costimulatory domains of receptors, such as CD28, aimed at improving CAR T-cell survival and function. Such CAR constructs are being employed today in CAR-engineered T-cell clinical trials for cancer indications. She is the author of more than 25 scientific publications and inventor on 13 issued U.S. patents and three published U.S. patent applications related to CAR T-cell technology and tumor vaccine therapies. Dr. Roberts was a postdoctoral fellow at Yale University and at the Laboratoire de Génétique Moléculaire des Eucaryotes (LGME) of the CNRS in Strasbourg, France. She received both her B.Sc. with honors and her Ph.D. from the University of Leeds in England.

Kite Pharma, Inc.
Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, California.

Molecular Switches: Enable Control of Cellular Immunotherapy

David M. Spencer, Ph.D.
Chief Scientific Officer, Bellicum Pharmaceuticals, Inc.

David M. Spencer, Ph.D., is a co-founder and chief scientific officer of Bellicum Pharmaceuticals. He joined the company on a full-time basis in December 2011, after 15 years at Baylor College of Medicine, where he was professor and vice chairman of pathology and immunology. He co-developed the chemical inducer of dimerization (CID) technology in the early 1990s, while he was a post-doctoral fellow at Stanford University, following receipt of a Ph.D. from MIT in 1991. Dr. Spencer is also a co-inventor of DeCIDe™ and CaspaCIDe™, the two CID applications that have since entered the clinic along with GoCART™ and CIDeCAR™ in late preclinical development. GoCART is based on CAR T-cell technology but relies on inducible costimulation, and CIDeCAR provides constitutive costimulation to CAR T cells with the CaspaCIDe suicide gene to modulate the immune response.

Dr. Spencer’s academic research program focused on CID, and he is the co-author of more than 70 peer-reviewed papers along with numerous patents. CID technology is now in use in thousands of laboratories worldwide, and Dr. Spencer continues to stay at the forefront of this field, pushing its potential applications in both Bellicum’s preclinical research activities and clinical applications.

Bellicum Pharmaceuticals, Inc.
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary chemical induction of dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Panel Discussion

Bios for the panelists who have presented or will present can be found in the indicated section of the book. Otherwise, they begin on the following page.

Moderator: Renier Brentjens, M.D., Ph.D., Director–Cellular Therapeutics, Memorial Sloan Kettering Cancer Center (Adoptive Cell Therapies)

Marcela Maus, M.D., Ph.D., Director–Cellular Immunotherapy, Massachusetts General Hospital (Adoptive Cell Therapies)

Michael Kalos, Ph.D., CSO–Cancer Immunobiology, Lilly Research Laboratories, Eli Lilly and Company (Combination Immuno-oncology Themes)

Margo Roberts, Ph.D., CSO, Kite Pharma (Adoptive Cell Therapies)

David Spencer, Ph.D., CSO, Bellicum Pharmaceuticals (Adoptive Cell Therapies)

Helen Tayton-Martin, Ph.D., COO, Adaptimmune (Adoptive Cell Therapies)

Christopher Haqq, M.D., Ph.D., CMO, Atara Biotherapeutics (Adoptive Cell Therapies)
Notes
Combination Immuno-oncology Themes
Immunosequencing in Immuno-oncology/Tumor Micro-Environment

Ilan “Lanny” Kirsch, M.D.
Senior Vice President-Translational Medicine, Adaptive Biotechnologies

Dr. Kirsch received his M.D. from Harvard University Medical School and subsequently completed his residency at Children’s Hospital Medical Center, Boston, Massachusetts, and his fellowship in pediatric hematology/oncology at the National Cancer Institute (NCI) in Bethesda, Maryland. Dr. Kirsch also completed a three-year postdoctoral fellowship in molecular genetics in the laboratory of Dr. Philip Leder at the National Institute of Child Health and Human Development. Subsequently he spent more than 20 years at the NCI as a basic researcher, attending physician, and, ultimately, chief of the genetics branch within the Center for Cancer Research. His research interests have been focused on cancer-specific genetic instability and cancer genetics. In 2005 Dr. Kirsch joined the biotech/pharma company Amgen as an executive director heading the oncology research group at Amgen Washington in Seattle. During the next six years, the Amgen Washington group was responsible for bringing a number of different therapeutic targets and modalities to Phase I trial evaluation. It also provided basic research support for many projects in late-stage clinical development or marketed. Dr. Kirsch has been an independent consultant to the biotech/pharma industry with extended assignments focused on the development of antibody therapeutics and molecular diagnostics. He currently serves as the senior vice president of translational medicine at Adaptive Biotechnologies in Seattle. Dr Kirsch is an author of more than 150 peer-reviewed manuscripts and over 30 books, chapters, or reviews.

Adaptive Biotechnologies

Adaptive Biotechnologies is the leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system. Adaptive brings the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive is also committed to translating immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. Visit www.adaptivebiotech.com for more information.

Targeting the Immunosuppressive Microenvironment

Julian Adams, Ph.D.
President–Research and Development, Infinity Pharmaceuticals, Inc.

Julian Adams, Ph.D., is president of research and development at Infinity Pharmaceuticals. He is responsible for the full spectrum of Infinity’s drug discovery, preclinical and clinical development strategy, and regulatory affairs activities. Prior to joining Infinity in 2003, Dr. Adams was the senior vice president of drug discovery and development at Millennium Pharmaceuticals. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy. He joined Millennium through its acquisition of LeukoSite in 1999, where he was senior vice president, research and development. Dr. Adams joined LeukoSite as a result of its acquisition of ProScript, Inc., where he had served as a member of the founding management team, executive vice president of research and development, and a member of the board of directors. Earlier in his career, Dr. Adams served in various positions, including director, medicinal chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune® (nevirapine) for HIV.

Dr. Adams is on the board of directors of Warp Drive Bio and the Princess Margaret Cancer Foundation and is on the scientific advisory boards of Cleave Biosciences and Stand Up to Cancer. He is an inventor of more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals.

Dr. Adams received his B.S. from McGill University and his Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. He also received the degree of Doctor of Science, honoris causa, from McGill University in 2012.

Infinity Pharmaceuticals, Inc.

Infinity is an innovative biopharmaceutical company dedicated to discovering, developing, and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. For more information on Infinity, refer to the company’s website at www.infi.com.
Emerging Biomarkers in Immuno-oncology

Michael Kalos, Ph.D.
Chief Scientific Officer–Cancer Immunobiology, Lilly Research Laboratories, Eli Lilly and Company

Dr. Kalos is a member of Lilly's Research Oncology Division, where he leads preclinical and translational efforts in cancer immunotherapy. Dr. Kalos is a recognized international key thought leader in the fields of immunotherapy and biomarkers, with more than 20 years' experience spanning biotech, academia, and big pharma. He has authored multiple high-impact primary and review articles and book chapters in the field of cancer immunotherapy, has been an invited speaker at national and international scientific meetings, and is a member of institutional and corporate scientific advisory boards and steering committees for international immunotherapy societies and working groups.

Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. The company was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, visit www.lilly.com.

Integrated Approach to Optimizing Cancer Immunotherapy

Robert B. Stein, M.D., Ph.D.
President–Research and Development and Chief Scientific Officer, Agenus Inc.

As chief scientific officer and head of research and development at Agenus Inc., Dr. Robert Stein is responsible for all aspects of R&D, including the antibody platforms. He joined Agenus in January 2014. Over his 35 years in the biopharmaceutical industry, he played a pivotal role in bringing Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta®, and Eliquis® to market. Prior to joining Agenus he held a number of progressively responsible senior management positions including CSO and senior vice president of research for Ligand Pharmaceuticals, executive vice president of research and preclinical development for Dupont Merck, president and CSO for Incyte Pharmaceuticals, president of Roche Palo Alto, and CEO of KineMed. From 1981 to 1990, Dr. Stein began his career at Merck, Sharp and Dohme. He holds an M.D. and a Ph.D. in physiology and pharmacology from Duke University.

Agenus Inc.

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach to target identification and validation, and for the discovery, development, and manufacturing of monoclonal antibodies that modulate targets of interest. The company's broad portfolio of novel checkpoint modulators and other immuno-modulatory monoclonal antibodies, vaccines, and adjuvants work in combination to provide the opportunity to create best-in-class therapeutic regimens. Agenus's heat shock protein-based vaccine, Prophage™, has successfully completed Phase II studies in newly diagnosed glioblastoma. The company is collaborating with Merck and Incyte to discover and develop multiple checkpoint modulators. For more information, visit www.agenusbio.com.
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells

John Lin, M.D., Ph.D.
Senior Vice President and Chief Scientific Officer, Rinat (Pfizer Inc.)

Dr. Lin has worked at biotech start-up Rinat since 2002, through its acquisition by Pfizer in 2006. Before that he was a postdoctoral fellow at Genentech Inc. from 1999 to 2001. He obtained a Ph.D. in biological and biomedical sciences from Harvard Medical School in 1998, and his M.D. from the College of Medicine of National Taiwan University in 1992.

Dr. Lin is dedicated to developing novel immunotherapeutic agents to address the key mechanisms of serious human diseases. He investigated beta amyloid peptide’s impact on age-related macular degeneration and Alzheimer’s disease. He independently conceived of the idea of passive immunotherapy targeting PCSK9 for LDL lowering in 2006. His research team also unveiled the mechanisms underlying the cytokine interleukin 7 in the pathogenesis of multiple sclerosis and type 1 diabetes. In 2013 his research responsibility expanded into leading the strategy of cancer immunology in Pfizer, including checkpoint inhibitors, co-stimulators, and CAR T-cell therapy. He is responsible for establishing Pfizer’s collaborations with MD Anderson Cancer Center’s Immunotherapy Platform (Jan. 2014), with Cellectis on CAR-T technology (June 2014), and with Kyowa H. Kirin on 4-1BB/CCR4 combination therapy in solid tumors (Sep. 2014), as well as the Merck KGaA PD-L1 partnership (Nov. 2014).

The Increasing Relevance of Vaccines in the Era of Checkpoints

James Gulley, M.D., Ph.D.
Chief–Genitourinary Malignancies Branch, Head–Immunotherapy Section, and Director–Medical Oncology Service, Center for Cancer Research, NIH

Dr. Gulley is an internationally recognized expert in immunotherapy for cancer. He serves within the Center for Cancer Research (CCR) of the National Cancer Institute as chief of the genitourinary malignancies branch, director of the medical oncology service, and head of the immunotherapy section. He has been instrumental in the clinical development of Prostvac, an experimental prostate cancer vaccine developed within the CCR, and is the principal investigator of the PROSPECT Trial, an international randomized Phase III study of Prostvac, which recently completed enrollment. He also has been instrumental in the clinical development of avelumab (EMD Serono/Pfizer), an anti-PDL1 antibody, for which the first-in-human study was done at the CCR and now has been given breakthrough designation by the FDA with multiple Phase III studies ongoing or planned. Dr. Gulley has been an investigator on over 60 trials, authored more than 200 scientific papers or chapters, and made numerous presentations at national and international meetings.

Rinat (Pfizer Inc.)

Rinat is dedicated to developing new protein-based therapeutics to improve human life. Rinat researchers use the latest scientific knowledge and apply novel approaches to discover new ways of treating disease. Cooperation and support for a high level of scientific freedom is encouraged to find the best answers to biological questions. Rinat was formed in 2001 as an independent, private biotech company. In 2006, it was acquired by Pfizer, and is the biotechnology unit within Pfizer Worldwide Research & Development, dedicated to doing its part to fulfill Pfizer’s mission of working together for a healthier world. Located in South San Francisco, California, Rinat provides the feel of a small company with the resources of a large pharmaceutical company in the heart of the biotech capital of the world.
Panel Discussion

Bios for the panelists who have presented or will present can be found in the indicated section of the book. Otherwise, they begin on the following page.

**Moderator: James Gulley, M.D., Ph.D.,** Chief–Genitourinary Malignancies Branch; Head–Immunotherapy Section, Director–Medical Oncology Service, Center for Cancer Research, NIH (Combination Immuno-oncology Themes)

**Robert Stein, M.D., Ph.D.,** President–Research and Development and CSO, Agenus (Combination Immuno-oncology Themes)

**Robert Sikorski, M.D., Ph.D.,** Senior Vice President–Global Clinical Development, Five Prime Therapeutics (Checkpoint/Immunomodulators)

**Paul Tumeh, M.D.,** Assistant Professor in Residence, Division of Dermatology, UCLA (Checkpoint/Immunomodulators)

**Taylor Schreiber, M.D., Ph.D.,** CSO, Heat Biologics (Therapeutic Vaccines: Stimulating the Immune System)

**Michael Kalos, Ph.D.,** CSO–Cancer Immunobiology, Lilly Research Laboratories, Eli Lilly and Company (Combination Immuno-oncology Themes)

**John Lin, M.D., Ph.D.,** Senior Vice President and CSO, Rinat (Pfizer) (Combination Immuno-oncology Themes)
PRESENTS

THE 5TH ANNUAL
Cancer Immunotherapy: A Long-Awaited Reality Conference

Thursday, March 26, 2015
New York Academy of Medicine
1216 5th Avenue, New York, NY 10029

SPONSORED BY:
MaidStone Life Sciences (MSLS) is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. As a strategic advisor and partner, MaidStone Life Sciences provides a full range of services to help our clients increase visibility, unlock stakeholder value, and access resources to grow their business. To accomplish this, we integrate investor relations, strategy, communications, and operational capabilities and apply them to carefully conceived plans that deliver results.

MSLS has an extensive network of venture capitalists, institutional investors, high net worth individuals, and other sources of capital for our clients to access.

For more information, visit the firm’s website at www.MaidstoneLS.com.

Janet L. Dally  
Founder and Managing Director

Janet L. Dally has more than 20 years of experience in the biotechnology, pharmaceutical and medical technology industries as an investor relations advisor, healthcare fund analyst, business development and medical device marketing manager, and microbiologist.

Before establishing MaidStone Life Sciences, she was Senior Partner at MD Becker Partners. She was also President of MontRidge, LLC, a boutique investor relations and strategic consulting firm specializing in the life science industry. She first joined MontRidge as Vice President in 1998. During her tenure at MD Becker and MontRidge, Ms. Dally built meaningful relationships with the executive management of life science clients and the US and European investment community resulting in increased institutional ownership, diversified shareholder base, sell-side analyst coverage, enhanced valuation and successful financing.

Prior to joining MontRidge, Ms. Dally was Vice President of Investor Relations at Burns McClellan, a life sciences communication firm. Ms. Dally has 6-years of experience as a Buy Side Analyst for the Merrill Lynch Healthcare Fund evaluating and recommending biotechnology, pharmaceutical, medical device and healthcare services firms. She also has direct pharmaceutical industry experience at both Sterling Drug and Forest Laboratories where she held executive positions in strategic planning, business development, licensing and M&A.

Ms. Dally has an M.B.A. from the Tepper School of Business, Carnegie Mellon University, a M.S. in Microbiology from Wagner College and a B.S. in Medical Technology from Rutgers University.

Ms. Dally undertakes an active leadership role as an advocate for the biotechnology industry.
ABOUT THE SPONSORS

ABR|Healthco

Healthco was founded in 2008, and subsequently became the exclusive healthcare division of ABR Investment Strategy, LLC, to become a leading, independent investment-advisory firm, focusing on healthcare companies. ABR |Healthco. provides institutional investors with uniquely unbiased and proprietary investment research, data points, and leading management access and value-add events. With an expertise in biopharmaceutical and medical devices companies, ABR |Healthco. seeks to help investors identify stock dislocations and growth opportunities. ABR |Healthco is lead by Manoj Garg, who has 15 years of sell-side equity research experience. Prior to founding Healthco, Manoj has also worked in a research capacity at Goldman Sachs, ING Barings, ABN Amro, and Piper Jaffray.

BioPharm Insight

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active Intel™ relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.”

www.biopharminsight.com

Great Minds Software (GMS)

Great Minds Software (GMS) is a leading supplier of contract management solutions since 1989, with experience in the life sciences, biotech, pharma and medical device communities as well as with investment firms involved in these industry segments. Our Contract Advantage™ product line provides the tools to manage Life Sciences contracts at all levels, whether as a central contract repository with email alerts for critical action dates, or for full automation from the point of requesting and authoring a contract, to workflow-based routing and approvals, digital signatures, and ongoing tracking of contract actions, to the final closeout of the contract. We offer cost-effective SaaS Solutions as well as systems installed behind the client’s firewall.

Kureczka/Martin Associates

Kureczka/Martin Associates offers a range of strategic communications, investor/public relations and business consulting services for life sciences companies. We help translate their science, products, and business strategies into stories that resonate with customers and patients. Our clients are developers and marketers of therapeutics, diagnostics, medical devices, and research tools that advance R&D and clinical medicine. We work with public and private companies, US and international firms as well as non-profit and governmental agencies. For more Information, please visit our website www.Kureczka-Martin.com.

Nature SciCafé

The Nature SciCafé is an exclusive invitation-only event hosted by the editors of Nature Biotechnology and Nature Medicine in the heart of the California, Texas, Massachusetts and New York Biotechnology hubs. Originally launched in 2008 the meetings have proven very successful in connecting both junior and more established scientists with a track record on translational research with life-science investors and industry R&D expertise.

For each event the project’s editorial team consisting of Victor Bethencourt (Managing Editor, Nature Publishing Group), Andrew Marshall (Chief Editor, Nature Biotechnology) and Christine Borowski (Chief Editor, Nature Medicine), nominates a group of three to six local university investigators that are shortlisted via their authorship of translational research articles published in the scientific literature.

ceeByte

ceeByte is a leading software development and consulting firm that provides strategic and creative technology solutions for some of the world’s most successful future-focused businesses. As a software solutions provider, we partner with our clients in four key areas – conception, development, implementation and maintenance with a strong emphasis on concepts behind technology and high corporate vision. We strive to develop long term relationships with our clients as their premier solutions provider.

Five Prime Therapeutics, Inc

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime’s comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company’s R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
SPEAKERS

David Berd, MD
CMO of AVAX Technologies

Dr. Berd served as the Chief Medical Officer for AVAX Technologies, Inc. He is the inventor of an autologous, hapten-modified human cancer vaccine, for which he has been awarded 8 patents. This AC Vaccine is currently under development by AVAX Technologies, Inc. As National Director for Immunotherapy at CTCA, Dr. Berd investigated the application of the AC vaccine to ovarian cancer. Prior to joining CTCA, Dr. Berd worked as an attending physician at Thomas Jefferson University Hospital, where he had taught since 1991. He also spent nine years as a research physician at Fox Chase Cancer Center. Over the course of his career, Dr. Berd has published 83 papers in numerous medical journals alongside dozens of editorials, reviews and abstracts.

Tom M. Brakel, MD
Senior Portfolio Manager and Senior Investment Analyst at Federated Investors, Inc.

Tom M. Brakel, M.D. is a Senior Portfolio Manager and Senior Investment Analyst at Federated Investors, Inc. Dr. Brakel serves as Senior Investment Analyst and Senior Portfolio Manager at Federated Equity Management Company of Pennsylvania. He joined the Federated Equity Management Company of Pennsylvania in 2003 and is responsible for research and analytical support in the domestic growth equity area. He serves as a Portfolio Manager of Advanced Series Trust - AST Federated Aggressive Growth Portfolio, Federated Equity Funds - Federated Kaufmann Small Cap Fund, Federated Equity Funds - Federated Kaufmann Fund and Federated Equity Funds - Federated Kaufmann Large Cap Fund. Mr. Brakel served as Vice President and Senior Biotech Analyst at New Vernon Associates, Inc. He served as a Biotech Analyst at BioPharma Fund, and Biotech and Pharmaceutical Analyst at Mehta Partners. Dr. Brakel earned an M.D. from Erasmus University at The Netherlands and an M.B.A. from Stanford University.

Dr. Renier J. Brentjen, MD, Ph.D.
Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Institute
Associate member on the faculty at MSKCC and an Attending Physician on the Leukemia Service

Dr. Brentjens obtained an MD/Ph.D. (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr. Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service. As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T Cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T Cell receptors termed chimeric antigen receptors (CARs). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T Cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T Cells” currently being translated to the clinical setting as second generation CAR modified T Cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other tumors including targeting the MUC-16 antigen expressed on ovarian carcinomas as well as the more ubiquitous WT-1 tumor associated antigen.
Joshua Brody, MD
Assistant Professor in Hematology and Medical Oncology
Director of the Lymphoma Immunotherapy Program at the Mount Sinai School of Medicine in New York City

Joshua Brody, MD is an Assistant Professor in Hematology and Medical Oncology and the Director of the Lymphoma Immunotherapy Program at the Mount Sinai School of Medicine in New York City. He is also a member of the Lymphoma Research Foundation’s (LRF’s) Mantle Cell Lymphoma Consortium (MCLC) and an LRF Career Development Award (CDA) grant recipient.

He received his MD from State University of New York (SUNY) Stony Brook School of Medicine and his BA in molecular and cellular biology from Harvard University. He completed his residency in Internal Medicine at Yale New Haven Hospital and his fellowship in Medical Oncology at Stanford University School of Medicine.

Dr. Brody’s current research focuses on two areas: lymphoma immunotherapy and a class of targeted therapies called B-cell receptor signaling inhibitors. One type of immunotherapy is cancer vaccines. Dr. Brody finds novel therapies which block the B-cell receptor signal pathways which lymphoma cells need to survive as one the most exciting things happening in the field today.

Chris Cain
Associate at RA Capital Management

Chris Cain is an associate at RA Capital Management, a crossover fund dedicated to evidence-based investing in healthcare and life science companies. He conducts research and analysis to build competitive landscapes of drugs in development for a variety of diseases, with a particular focus in oncology indications and related mechanisms of action. He holds a BA in Biology from the UC Santa Barbara College of Creative Studies and a Ph.D. in Biochemistry and Molecular Biology from UC San Francisco. His doctoral research examined the evolution of transcriptional regulatory circuits controlling cell morphology and pathogenesis in fungi. Prior to RA Capital, Chris wrote for BioCentury Publications and the Science-Business eXchange (SciBX), where he evaluated the clinical and commercial potential of novel molecular targets and drug discovery approaches emerging from academic labs.

Martin A. “Mac” Cheever, MD
Director of the NCI funded Cancer Immunotherapy Trials Network (CITN), Member of the Fred Hutchinson Cancer Research Center and Professor of Medicine, University of Washington.

The CITN has established a productive network of leading immunotherapy investigators from 32 foremost institutions to implement, design and conduct novel biologically dictated early phase immunotherapy trials using agents and combinations to demonstrate proof-of-concept essential to proceed to Phase III pivotal trials and to provide high quality immunogenicity and biomarker data that elucidates mechanisms of response.

The CITN has ongoing trials with anti-CD40 (dendritic cell activator), Flt3L (dendritic cell growth factor), poly ICLC (vaccine adjuvant), IL15 (T Cell and NK cell activator and growth factor), IL7 (T Cell homeostatic growth factor), anti-PD1 (T Cell checkpoint inhibitor) and an IDO inhibitor (inhibitor of cancer and T Cell induced immune suppression).
Carl L. Gordon, Ph.D., CFA  
Founding Partner and Co-Head of Global Private Equity at OrbiMed

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.

Seth Ettenberg, Ph.D.  
Chief Scientific Officer, Unum Therapeutics

Seth Ettenberg is the Chief Scientific Officer at Unum Therapeutics. Unum is discovering and developing new cellular immunotherapies for cancer using its proprietary Antibody-Coupled T Cell Receptor (ACTR) technology. Seth is responsible for the company’s overall scientific direction and strategy, building and managing the research team, interacting with the external research environment, and helping to bring the promise of Unum’s new technology to patients in need. He has a strong track record of immuno-oncology experience, having taken multiple biologics programs through clinical development during his career.

Prior to Unum, Seth served as the Head of Novartis Oncology Biotherapeutics, Cambridge site. In this role, Seth led projects in all stages of development from target identification and validation through Phase 2 clinical trials. While at Novartis Seth had a demonstrated track record of invention and development with a variety of therapeutic modalities including naked antibodies, antibody drug conjugates, and novel therapeutic scaffolds. In addition, Seth was responsible for building and leading the Novartis Cell and Gene Therapy research team in collaboration with the University of Pennsylvania to develop chimeric antigen receptor T Cell therapeutics.

Prior to Novartis, Seth was a senior research scientist at CuraGen Corporation where he was responsible for the discovery and characterization of novel oncology targets and antibodies. Before moving to industry, Seth received his formal scientific training studying the underlying mechanisms of tumor formation and receptor tyrosine kinase regulation while in the Genetics Branch of the National Cancer Institute.
James L. Gulley, MD, Ph.D.
Chief, Genitourinary Malignancies Branch
Director, Medical Oncology Service, Ctr. for Cancer Research, NIH

Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He graduated from Loma Linda University in California with a Ph.D. in microbiology in 1994 and an M.D. in 1995. As part of this eight-year M.D./Ph.D. Medical Scientist Training Program he completed a dissertation on tumor immunology. Dr. Gulley completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI. He has served as Principal Investigator or Associate Investigator on more than 60 trials.

Dr. Gulley has received numerous awards, including the 2010 Presidential Early Career Award for Scientists and Engineers (PECASE), the highest award bestowed by the U.S. government on outstanding scientists early in their careers. He serves on many national and NIH boards and committees. Dr. Gulley has authored more than 180 scientific papers and book chapters, edited 4 books and has made numerous invited presentations at national and international meetings.

Michael Kalos, Ph.D.
Chief Scientific Officer, Cancer Immunobiology of Eli Lilly and Co.

Dr. Kalos joined Eli Lilly in October 2013. As a member of Lilly’s Research Oncology Division, Michael leads efforts to further develop the Cancer Immunotherapy Program at Eli Lilly. Current efforts are focused on steering preclinical development of the existing internal pipeline and establishing a robust and integrated program to discover and develop a robust immunotherapy pipeline at Eli Lilly.

Dr. Kalos is a recognized international key opinion leader in the fields of biomarkers and immunotherapy. He has authored multiple high-impact primary and review articles as well as book chapters in the field of cancer immunotherapy, has been an invited speaker at national and international scientific meetings, has been a member of institutional and corporate scientific advisory boards, and is an active member of steering committees for international immunotherapy working groups.

Ilan “Lanny” Kirsch, MD
Senior Vice President of Translational Medicine for Adaptive Biotechnologies

Dr. Kirsch received his M.D. from Harvard University Medical School and subsequently completed his Residency at Children’s Hospital Medical Center, Boston, Massachusetts and his Fellowship in Pediatric Hematology/Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland. Dr. Kirsch also completed a three-year postdoctoral fellowship in molecular genetics in the laboratory of Dr. Philip Leder at the National Institute of Child Health and Human Development. Subsequently Dr. Kirsch spent over 20 years at the NCI as a basic researcher, attending physician, and, ultimately, Chief of the Genetics Branch within the Center for Cancer Research. The research interests of Dr. Kirsch have been focused on cancer specific genetic instability and cancer genetics. In 2005 Dr. Kirsch joined the biotech/pharma company, Amgen, as an Executive Director heading the Oncology Research group at Amgen Washington in Seattle. Dr. Kirsch has been an independent consultant to the biotech/pharma industry with extended assignments focused on the development of antibody therapeutics and molecular diagnostics. He currently serves as the Senior Vice President of Translational Medicine for the immune receptor repertoire profiling company, Adaptive Biotechnologies, Seattle, Washington. He is an author of more than 140 peer-reviewed manuscripts and over 30 books, chapters, or reviews.
Holbrook Kohrt, Ph.D.
Assistant Professor of Medicine (Oncology) Stanford University Medical Center

Holbrook Kohrt, an Assistant Professor at Stanford Cancer Institute currently investigates novel therapeutic strategies to enhance anti-tumor immunity. Dr. Kohrt attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar and American Society of Hematology Research Fellow. During this he developed, validated, and nationally implemented a nomogram for risk prediction in early stage breast cancer. He trained in Internal Medicine at Stanford through the Clinical Investigator Pathway and completed fellowship in Hematology and Oncology at Stanford with a research focus on preclinical models of novel immunomodulatory antibodies. Dr. Kohrt received his Ph.D. in clinical trial design and tumor immunology from Stanford with a thesis including the first report of an agonistic monoclonal antibody capable of enhancing the efficacy of tumor-targeting therapeutics. This antibody is now in Phase 1/2 clinical trials, only 3 years since first preclinical research efforts. As faculty at Stanford, Dr. Kohrt is developing novel vaccine strategies that induce tumor antigen specific immunity prior to infusing the donor inoculum and improve graft-versus-tumor reactions without exacerbation of graftversus- host disease. His studies also include efforts to identify and develop immunomodulatory antibodies targeting immune effector cells subsets, such as natural killer cells, which enhance the anti-tumor activity of tumor-targeting antibodies.

Reiner Laus, MD
President and CEO of Annias Immunotherapeutics
Founder and Former President & CEO at BN ImmunoTherapeutics
Former Vice President of Research & Development at Dendreon Corporation

Reiner Laus, MD has worked on developing cancer immunotherapeutics for over 20 years. At BN ImmunoTherapeutics, Dr Laus focused on the development of recombinant poxviral vaccines including PROSTVAC and CV301 for the immunotherapy of cancer. Prior to this, Dr. Laus held the position of Vice President of Research and Development at Dendreon Corporation, where he worked for 11 years since Dendreon's inception in 1993. During his tenure at Dendreon, Dr. Laus invented PROVENGE, the first cancer vaccine to get approved by the FDA, and was instrumental in its development. He is also author of key patents relating to this product. Previously, Dr. Laus held academic appointments at the University of Kiel, Germany and at Stanford University, California.

Dr. Ignacio Melero, MD, Ph.D.
Professor of Immunology at the University of Navarra Medical school

Ignacio Melero earned an MD degree from the University of Navarra School of Medicine (1988) and was trained as a resident in clinical immunology at Hospital de la Princesa (Universidad Autonoma de Madrid). He also attained a Ph.D. degree working with Dr. Miguel Lopez-Botet pioneering the characterization of NK cell inhibitory receptors (KIRs) In 1994 he moved to Seattle (USA) where he worked on tumor immunology and immunotherapy, studying T Cell ignorance of tumor antigens and the role of T Cell costimulation in mouse models of cancer. His studies of that time on CD137-mediated co-stimulation of curative antitumor immune responses have received much attention by the immunotherapy of cancer community and have resulted in therapeutic agents undergoing phase II clinical trials. Since 1998 he returned to Navarra University where he currently serves as a full professor of Immunology at the Clinica Universidad de Navarra and at the investigation centre CIMA. His current areas of research are focused on from bench to bedside translational research with cell, gene and monoclonal antibody-mediated strategies of immunotherapy for cancer.
Col. George E. Peoples, MD, FACS
Director of the Cancer Vaccine Development Program, Chairman of the Cancer Care Program, Professor of Surgery at the Uniformed Services University of the Health Sciences, and Adjunct Professor of Surgical Oncology at MDACC

COL (ret) George E. Peoples, MD, FACS recently retired from 30 years of active duty as a surgeon and research scientist in the military. He is the Founder and Director of the Cancer Vaccine Development Program (CVDP) which is associated with the Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD. The CVDP has 15 years of experience in discovering, developing, and clinical testing of cancer vaccines - four of which have been licensed for commercial development. With his retirement, the CVDP now has a commercial counterpart, Cancer Insight, LLC, which is a boutique cancer immunotherapy CRO currently conducting multiple phase I and II trials. Dr Peoples serves as the Founder and CEO of Cancer Insight, LLC and as the CMO for Orbis Health Solutions, LLC. He also serves on the SAB for Galena Biopharma, Generex (Antigen Express), and Immunocellular Therapeutics, and he has consulted for a dozen different biotech and small pharma companies. Additionally, Dr Peoples is a Professor of Surgery at USUHS and a Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). He is the past Chair of the Cancer Program, San Antonio Military Medical Center (SAMMC) and the past Deputy Director of the United States Military Cancer Institute. Dr Peoples served as the Chief of Surgical Oncology at Walter Reed Army Medical Center (WRAMC) (1998-2006) and at SAMMC (2006-2014). He is a graduate of the United States Military Academy, West Point (1984) and the Johns Hopkins School of Medicine (1988). He completed his surgical training at Harvard’s Brigham and Women’s Hospital, and during that time, also completed a postdoctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School (1988-1996). He then completed a surgical oncology fellowship at MDACC (1998) before becoming Chief of Surgical Oncology at WRAMC. He has written extensively on the immune response to cancer with over 300 peer-reviewed manuscripts, abstracts, and book chapters.

Robert Pierce, MD, Ph.D.
Chief Scientific Officer at OncoSec Medical

Dr. Robert H. Pierce is the Chief Scientific Officer at OncoSec Medical. He joined OncoSec from Merck Research Labs where he was the Executive Director/Member of the Global Anti-PD-1 Development Team. Dr. Pierce is well regarded for his career-long research into mechanisms of immune tolerance. He is the co-author of over fifty peer-reviewed journal articles and book chapters. Dr. Pierce received his post-doctoral training at the University of Washington, Seattle, WA, his graduate education and training at Brown University School of Medicine in Providence, RI, and received his undergraduate education at Yale University in New Haven, CT. As a Fulbright Award recipient, Dr. Pierce studied Philosophy at the Albert-Ludwigs-University in Freiburg, Germany.
Neil H. Segal, MD, Ph.D.
Medical Oncologist at Memorial Sloan Kettering Cancer Center

Dr. Neil H. Segal is medical oncologist specializing in the treatment of patients with gastrointestinal cancers at Memorial Sloan Kettering Cancer Center. His research interests focus on the development of new therapies. In particular, he is investigating innovative ways to use the immune system to treat cancer. Dr. Segal is Deputy Director of the Immunology Group at Memorial Sloan Kettering.

Dr. Segal received his MD, Ph.D., from the University of the Witwatersrand (South Africa). He did his Residency at NYU Medical Center and was a Fellow at Memorial Sloan Kettering Cancer center.

Dr. Robert Sikorski, MD, Ph.D.
Vice President of Global Clinical Development at Five Prime Therapeutics, Inc.

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), Robert Sikorski, M.D., Ph.D., is Vice President of Global Clinical Development. Dr. Sikorski oversees the global clinical development activities for Five Prime’s product candidates. Dr. Sikorski joins Five Prime from MedImmune (the Biologics Division of AstraZeneca, PLC) where he was Senior Director, Global Oncology Research and Development, leading the development of a portfolio of oncology therapeutics with a focus on immune-mediated mechanisms and supporting partnering efforts, including those related to assets targeting PD1, CTLA4, and OX40. Prior to that, he was Director, Global Oncology Research and Development at Amgen, where he led the development of several oncology drug candidates. His seminal work on panitumumab (now marketed as Vectibix®) led to the drug’s approval with a first-in-class biomarker selection strategy based on KRAS genotype. In earlier positions, he served as a medical affairs consultant to Genzyme and as Chief Technology Officer at the biomedical data acquisition and analytics firm, Mednav, until acquisition. Dr. Sikorski received his M.D. and Ph.D. from The Johns Hopkins University School of Medicine through a Medical Scientist Training Program scholarship. He completed his residency at Massachusetts General Hospital and an oncology fellowship at The Johns Hopkins Oncology Center, and is board certified in both oncology and internal medicine. Dr. Sikorski began his career as a Howard Hughes Research Fellow and Visiting Scientist at the National Cancer Institute and the National Human Genome Research Institute in the laboratory of Nobel Laureate, Harold Varmus.
David M. Spencer, Ph.D.
Co-Founder and Chief Scientific Officer at Bellicum Pharmaceuticals

David Spencer is a Co-Founder of Bellicum with Dr. Slawin. He joined Bellicum in 2012 as Chief Scientific Officer. Dr. Spencer is the original inventor of CID technology, and together with Dr. Slawin, developed the first clinical applications of the technology, DeCIDe® and CaspaCIDe® that are now advancing in human clinical trials. Prior to joining Bellicum, he served as Professor and Vice Chairman of Pathology & Immunology, Baylor College of Medicine, during which time he was a scientific advisor to the Company. Dr. Spencer oversees a robust research program focused on CID clinical applications and supports clinical development of our CID-enabled products. He earned his Ph.D. at Massachusetts Institute of Technology and was a postdoctoral fellow at Stanford University.

Scott C. Stromatt, MD
Senior Vice President and Chief Medical Officer, Emergent BioSolutions, Inc.

Dr. Stromatt has a medical degree from the University of Chicago and a MBA from the University of Colorado. He is board certified in Internal Medicine and has over 26 years of biopharmaceutical experience, including three years as a biotechnology analyst for a Wall Street investment firm.

Dr. Stromatt has conducted Phase 1 to Phase 4 clinical trials in a wide variety of clinical indications, including oncology, rheumatology, pulmonology, gastroenterology and neurology. He has worked on various regulatory filings including INDs, NDAs, BLAs and MAAs. His oncology experience covers the hematologic malignancies of CLL, NHL, APL, MDS and MM, and the solid tumor malignancies of prostate, lung and ovarian. Additionally, he has experience in medical affairs with extensive market and brand management support. His focus since 2002 has been the clinical development of oncology and immunology products.

Dr. Paul C. Tumeh
Assistant Professor in the Department of Medicine at UCLA

The identification of immune cell-types that mediate tumor rejection during PD-1 blockade remain poorly understood and represents a top priority in cancer medicine. His research program aims to address this challenge and has two main objectives: i) to identify niches (i.e., discrete cellular microenvironments) within tumors that drive or inhibit response to PD1/PDL1 blocking therapies, and ii) to isolate immune cell-types (e.g., myeloid-derived cells) from their native context in order to investigate the molecular mechanisms underlying response and non-response to anti-PD1 therapy. His lab has established approaches that include slide-based, quantitative multiplexed immunohistochemistry platforms, immune laser-capture microdissection, and in-situ spatially resolved gene expression profiling. He is currently focused on understanding the phenotype and function of PD-L1+ myeloid-derived cells and how these cells may impact treatment outcome. Paul has an active melanoma specialty clinic and serves as a sub-investigator on all melanoma immunotherapy clinical trials at UCLA Medical Center. His most recent publications include articles in Nature, New England Journal of Medicine, and Clinical Cancer Research.
Adaptive Biotechnologies

Adaptive Biotechnologies is the pioneer in combining high-throughput sequencing and expert bioinformatics to profile T Cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of the immunoSEQ™ platform into laboratories around the world to drive groundbreaking research. We are also committed to translating our immunosequencing discoveries into clinical diagnostics to improve patient care in cancer and other immune-mediated diseases.

Agenus Inc. (AGEN) agenusbio.com

Agenus is developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. The company’s proprietary discovery engine Retrocyte Display® is designed to rapidly generate high quality therapeutic antibody drug candidates using a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. A portfolio of checkpoint modulator programs is advancing in preclinical development. The company’s heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. Agenus’ QS-21 Stimulon adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen and includes several candidates in Phase 3 trials. Among Agenus and its partners, 23 programs are in clinical development.

Annias Immunotherapeutics, Inc.

Annias Immunotherapeutics, Inc. is a clinical stage immuno-oncology company focused on the development of novel immunotherapeutic approaches to the treatment of cancers that contain Cytomegalovirus (CMV). The company’s approach is based on a patented and proprietary immunotherapeutic platform, discovered at Duke University, which harnesses the body’s immune system to recognize, attack and destroy tumor cells containing CMV. CMV is over-expressed in a variety of human cancers including significant and homogeneous expression in almost all glioblastoma, but not in normal brain tissue. Annias Immunotherapeutics focuses on this opportunity to use CMV proteins as tumor-specific targets. For more information, please contact Reiner Laus, M.D. President and CEO of Annias Immunotherapeutics at info@anniasimmuno.com or visit our website at www.anniasimmuno.com.
**Bellicum Pharmaceuticals**

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T Cell therapy, and dendritic cell vaccines.

---

**Cell Medica**

Cell Medica is a cellular immunotherapy company engaged in the development, manufacturing and marketing of novel treatments for cancer and infectious disease. In the field of cancer immunotherapy, Cell Medica has recently launched a multinational Phase II clinical trial for an autologous T Cell therapy which targets a range of cancers associated with the oncogenic Epstein Barr Virus (EBV) including Hodgkin and non-Hodgkin lymphomas as well as nasopharyngeal carcinoma. The Company’s Cytovir™ product family for immune reconstitution is for the treatment of infections caused by latent viruses in immunosuppressed patients following allogeneic haematopoietic stem cell (bone marrow) transplant.

---

**Costanoan Immunotherapies, Inc.**

Costanoan Immunotherapies, Inc. (Costanoan) is a U.S.-based company engaged in the development of immunomodulatory therapeutics and diagnostics for cancers and chronic inflammatory diseases based on a unique bio-nanoparticle (BNP) technology for antigen-presentation. The BNP platform offers a blank canvas for the design and highly cost-effective production of specific therapies on a biocompatible, biodegradable support. BNPs are engineered and produced via a single-step, biofermentation process to display one or more proteins or peptides (e.g. antigens, cytokines, chemokines, immunomodulators) on their surfaces in a regular, high-density display that prompts the body’s immune system to treat the BNPs like an invading pathogen. BNPs can be engineered to display simultaneously not only antigens, but adjuvants like lipids or carbohydrates on the BNP surface. This capability enables Costanoan to design BNPs that present unique combinations of antigens and adjuvants to the immune system to elicit tumor-specific responses. Costanoan plans to apply this technology initially to the treatment of Non-Small Cell Lung Cancer (NSCLC).
Emergent BioSolutions

Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about the company may be found at www.emergentbiosolutions.com.

Five Prime Therapeutics, Inc.

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime’s comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company’s R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to generate and/or expand antigen-specific cytotoxic T Cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design’s three on-going immuno-oncology clinical programs are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.
Presenting Companies

TapImmune Inc.

TapImmune Inc (OTCBB: TPIV) is a Seattle-based clinical stage immunotherapy company specializing in the development of innovative immunotherapies for the treatment of cancer and infectious disease. The Company's product compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T Cells, helper T Cells and to restore or further augment antigen presentation with proprietary nucleic acid-based expression systems (PolyStart™). TapImmune's lead products for the treatment of HER2/neu breast cancer and ovarian and triple negative breast cancer have completed Phase I and are ready to progress into Phase II in 2015. The Company's immunotherapeutics may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.

OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
Trillium Therapeutics, Inc.

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors.

Unum Therapeutics

Unum is a clinical-stage biotechnology company discovering and developing cellular immunotherapies for cancer. Unum’s proprietary Antibody-Coupled T Cell Receptor (ACTR) platform, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers, including solid tumors.
<table>
<thead>
<tr>
<th>TIME</th>
<th>PANEL DISCUSSIONS &amp; PLENARY SESSIONS</th>
<th>TIME</th>
<th>CORPORATE PRESENTATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45–8:20am</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:20–8:30am</td>
<td>Opening Remarks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 8:30–9:00am| Keynote speaker: Martin A. “Mac” Cheever MD-- Principal Investigator, Cancer Immunotherapy Trials Network, Member, Fred Hutchinson Cancer Research Center Cancer Immunotherapy Overview- Professor of Medicine/Oncology, University of Washington  
“High-Priority Immunotherapy Agents in Development” |      |                         |
| 9:00–9:30am| CAR T Cell Therapy for Cancer: We have a Model A Ford, Can we Build a Ferrari?  
Renier J. Brentjens, MD-- Director- Cellular Therapeutics, Memorial Sloan Kettering Cancer Center |      |                         |
| 9:30-9:50am| Next Gen CAR-T Cells: Safety and Efficacy  
David M. Spencer, Ph.D. - CSO of Bellicum | 9:30-10:00am | Immune Design |
| 9:50-10:10am| ADAPTIR™ Bispecific Redirected T Cell Cytotoxicity  
Scott C. Stromatt, MD-- Chief Medical Officer and Senior Vice President of Clinical, Emergent BioSolutions, Inc. | 10:00-10:30am | Trillium Therapeutics |
| 10:10-10:55am| Panel-Chimeric Antigen Receptor/Engineered T Cells for Cancer Immunotherapy: Progress and Challenges  
CAR/TCR Engineered TCells: What Solid Tumors will be Treated Effectively?  
What Role does the Combination with Checkpoint Inhibitors play?  
• Moderator-Renier J. Brentjens- Director-, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center  
• Mac Cheever, MD - Principal Investigator, Cancer Immunotherapy Trials Network, Member, Fred Hutchinson Cancer Research Center Cancer Immunotherapy Overview- Professor of Medicine/Oncology, University of Washington  
• Seth Ettenberg, Ph.D. - CSO of Unum Therapeutics  
• Gregg Sando - CEO of Cell Medica  
• David M. Spencer, Ph.D. - CSO of Bellicum  
• Scott C. Stromatt, MD - Chief Medical Officer and Senior Vice President of Clinical, Emergent BioSolutions, Inc.  
• Michael Kalos, Ph.D. - Chief Scientific Officer, Cancer Immunobiology |      |                         |
| 10:55–11:05am| Coffee Break                                                   |      |                         |
| 11:05–11:25am| Immunotherapy                                                  |      |                         |
| 11:25–11:50am| Agonist Immunostimulatory Monoclonal Antibodies: Combining Positive and Negative Thinking  
Ignacio Melero, MD- Professor of Immunology and Consultant  
CIMA, CUN and Medical School, University of Navarra | 11:30–12:00pm | Costanoan Immunotherapies |
### Panel Discussions & Plenary Sessions

**Room 20**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:50 - 12:35pm | Panel – Checkpoint Modulators – Next Generation  
- Robert Stein, MD, Ph.D. - CSO of Agenus  
- James Gulley, MD, Ph.D. – Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Ctr. for Cancer Research, NIH  
- Ignacio Melero, MD- Professor of Immunology and Consultant CIMA, CUN and Medical School, University of Navarra  
- Robert Sikorski, MD. Ph.D.- VP of Global Clinical Development- Five Prime Therapeutics  
- Bob Uger , Ph.D.-CSO of Trillium Therapeutics  
- Paul Tumeh, MD-Clinical Instructor, Department of Medicine, Dermatology Member, JCCC Tumor Immunology Program Area, UCLA  
- Robert Stein, MD, Ph.D. - CSO of Agenus  
- James Gulley, MD, Ph.D. – Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Ctr. for Cancer Research, NIH  
- Ignacio Melero, MD- Professor of Immunology and Consultant CIMA, CUN and Medical School, University of Navarra  
- Robert Sikorski, MD. Ph.D.- VP of Global Clinical Development- Five Prime Therapeutics  
- Bob Uger , Ph.D.-CSO of Trillium Therapeutics  
- Paul Tumeh, MD-Clinical Instructor, Department of Medicine, Dermatology Member, JCCC Tumor Immunology Program Area, UCLA  |
| 12:35 - 1:00pm | Unleashing the Power of the Immune System Through Combination Therapy  
James Gulley, MD, Ph.D. – Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Ctr. for Cancer Research, NIH  |
| 1:00 - 1:25pm | Lunch |
| 1:25 - 2:10pm | Panel – Combination Themes  
What Combinations will Convert Non-responders to Responders?  
What Combinations will Improve Response among Responders?  
- Moderator: Ignacio Melero- MD- Professor of Immunology and Consultant CIMA, CUN and Medical School, University of Navarra  
- James Gulley, MD, Ph.D. – Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Ctr. for Cancer Research, NIH  
- Robert Stein, MD, Ph.D. - CSO of Agenus Inc.  
- Paul Tumeh, MD-Clinical Instructor, Department of Medicine, Dermatology Member, JCCC Tumor Immunology Program Area, UCLA  
- Mac Cheever, MD- Principal Investigator, Cancer Immunotherapy Trials Network, Member, Fred Hutchinson Cancer Research Center Cancer Immunotherapy Overview- Professor of Medicine/Oncology, University of Washington  
- Carlos Paya, MD, Ph.D.. President and CEO of Immune Design  |
| 2:10 - 2:30pm | Immunosequencing in the Service of Immuno-oncology  
Ilan "Lanny Kirsch", MD- SVP, Translational Medicine of Adaptive Biotechnologies  |
| 2:30 - 2:45pm | "Immunomodulation of Anti-Tumor Responses: The Fundamental Things Apply."  
David Berd, MD- CMO of AVAX Technologies  |
| 2:45 - 3:10pm | "Turning a Tumor into a Vaccine Factory: In situ Vaccination for Low-grade Lymphoma"  
Joshua Brody, MD- Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai  |
| 3:10- 3:35pm | "Emerging Concepts in Immunotherapy of GI Cancers"  
Neil Segal-MD, PH.D.- Deputy Director –Immunotherapy Group, Memorial Sloan Kettering  |

**Room 21**

<table>
<thead>
<tr>
<th>Time</th>
<th>Corporate Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 12:30pm</td>
<td>OncoSec Medical</td>
</tr>
<tr>
<td>12:30 - 1:00pm</td>
<td>Emergent BioSolutions</td>
</tr>
<tr>
<td>1:30 - 2:00pm</td>
<td>Unum Therapeutics</td>
</tr>
<tr>
<td>2:00 - 2:30pm</td>
<td>Annias Immunotherapeutics</td>
</tr>
<tr>
<td>2:30 - 3:00pm</td>
<td>Agenus Inc.</td>
</tr>
<tr>
<td>3:00 - 3:30pm</td>
<td>Cell Medica</td>
</tr>
<tr>
<td>TIME</td>
<td>PANEL DISCUSSIONS &amp; PLENARY SESSIONS ROOM 20</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>3:35- 3:45pm</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>3:45- 4:00pm</td>
<td>&quot;Better Immunization Methods and Better Targets: Next Generation Cancer Vaccines&quot;</td>
</tr>
<tr>
<td></td>
<td>Reiner Laus, MD, CEO of Annias Immunotherapeutics</td>
</tr>
<tr>
<td>4:00- 4:35pm</td>
<td>What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapies?</td>
</tr>
<tr>
<td></td>
<td>• Moderator: Mac Cheever, MD- Fred Hutchinson Cancer Research Center Cancer Immunotherapy Overview</td>
</tr>
<tr>
<td></td>
<td>• Robert Stein, MD, Ph.D- CSO of Agenus Inc.</td>
</tr>
<tr>
<td></td>
<td>• Reiner Laus, MD, CEO of Annias Immunotherapeutics</td>
</tr>
<tr>
<td></td>
<td>• Robert Pierce, MD- CMO of OncoSec Medical</td>
</tr>
<tr>
<td></td>
<td>• David Berd, CMO of AVAX Technologies</td>
</tr>
<tr>
<td></td>
<td>• Glynn Wilson, Ph.D.- CEO TapImmune</td>
</tr>
<tr>
<td>4:35-5:05pm</td>
<td>Panel- Immunotherapies in the Adjuvant Setting</td>
</tr>
<tr>
<td></td>
<td>• Moderator: George E Peoples, MD, FACS, COL (ret), MC, USA, Founder and CEO, Cancer Insight, LLC, Director, Cancer Vaccine Development Program, Professor, Surgery, Uniformed Services University, Professor (adjunct), Surgical Oncology, MD Anderson Cancer Center</td>
</tr>
<tr>
<td></td>
<td>• David Berd, MD- CMO of AVAX Technologies</td>
</tr>
<tr>
<td></td>
<td>• Tracy Thompson- CEO of Costanoan Immunotherapies</td>
</tr>
<tr>
<td>5:05-5:25pm</td>
<td>Taking the Fight to the tumor - a Rationale for Intratumoral Electroporation of Immunomodulators</td>
</tr>
<tr>
<td></td>
<td>Robert Pierce, MD- CMO of OncoSec Medical</td>
</tr>
<tr>
<td>5:25-6:00pm</td>
<td>Wall Street Perspectives on Immuno-oncology</td>
</tr>
<tr>
<td></td>
<td>• Moderator: Y. Katherine Xu, Ph.D., Equity Research – Biotechnology,William Blair &amp; Company</td>
</tr>
<tr>
<td></td>
<td>• Carl Gordon, Ph.D.- Partner of OrbiMed</td>
</tr>
<tr>
<td></td>
<td>• Chris Cain, Ph.D- RA Capital</td>
</tr>
<tr>
<td></td>
<td>• Tom Brakel, MD- Federated Kaufmann</td>
</tr>
<tr>
<td>6:00 – 7:00pm</td>
<td>Wine and cheese networking reception and closing remarks–Presidents Room</td>
</tr>
</tbody>
</table>